11 Jun 2019
Melvyn’s story
In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.
“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.
“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.
“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”
Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.
“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.
“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.
“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”
Professor Francesco Dazzi
“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.
“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”
Related posts
4 September 2023
Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer
New research launched today by Leukaemia Care and Leukaemia UK reveals that less than 1% (0.4%) of UK adults can accurately identify the four most common symptoms of leukaemia –…
20 September 2021
Leukaemia charities unite in Blood Cancer Awareness Month to improve diagnosis and the chances of survival
Leading UK leukaemia charities Leukaemia Care and Leukaemia UK have announced a new collaboration to increase awareness of the signs and symptoms of leukaemia and drive improvements in the diagnosis of the disease. The campaign, Spot Leukaemia, is running throughout September – Blood Cancer Awareness Month.
1 August 2022
A research breakthrough targets cancer over healthy tissue, bringing possibility of a new treatment option for most deadly type of leukaemia
A new scientific paper published on 22nd June in Science Translational Medicine, announced a breakthrough by Leukaemia UK-funded scientist Dr William Grey that could lead to a vital new treatment option for…
4 June 2022
Leukaemia UK is looking for volunteers for their Patient Experience Advisory Panel
Leukaemia UK is committed to championing advancements in better treatments and care for all. We want to ensure the needs of patients are at the heart of everything we do, and that the voices of people affected by leukaemia and related conditions are being heard. That is why we are setting up a Patient Experience Advisory Panel.